Sensei Biotherapeutics to Participate in the 13th Annual Jefferies Global Healthcare Conference
Sensei Biotherapeutics, Inc. (NASDAQ: SNSE) will present at the 13th Annual Jefferies Global Healthcare Conference in London on November 17, 2022, at 7:25 a.m. GMT. The presentation, led by CEO John Celebi, will highlight the company's focus on developing innovative immuno-oncology therapeutics, particularly through its TMAb™ platform. The lead candidate, SNS-101, targets the VISTA checkpoint in the tumor microenvironment to enhance T cell activation against tumors. A webcast of the presentation will be available on Sensei’s website for approximately 90 days.
- None.
- None.
BOSTON, Nov. 02, 2022 (GLOBE NEWSWIRE) -- Sensei Biotherapeutics, Inc. (NASDAQ: SNSE), an immuno-oncology company focused on the discovery and development of next generation therapeutics for cancer, today announced that John Celebi, President and Chief Executive Officer, will present at the 13th Annual Jefferies Global Healthcare Conference, being held in London, United Kingdom, on Thursday, November 17, 2022, at 7:25 a.m. GMT.
A webcast of Sensei’s presentation will be available in the Investors section of the Sensei website. A replay of the webcast will be on the website for approximately 90 days following the event. Registration for the live webcast is available here.
About Sensei Biotherapeutics
Sensei Biotherapeutics (NASDAQ: SNSE) is an immuno-oncology company focused on the discovery and development of next-generation therapeutics for cancer patients. Through its TMAb™ (Tumor Microenvironment Activated biologics) platform, Sensei develops conditionally active therapeutics designed to disable checkpoints and other immunosuppressive signals selectively in the tumor microenvironment to unleash T cells against tumors. Sensei’s lead investigational candidate is SNS-101, a conditionally active antibody designed to block the V-domain Ig suppressor of T cell activation (VISTA) checkpoint selectively within the low pH tumor microenvironment, where VISTA acts as a suppressor of T cells by binding the receptor PSGL-1. For more information, please visit www.senseibio.com, and follow the company on Twitter @SenseiBio and LinkedIn.
Investor Contact:
Michael Biega
Senior Director, Investor Relations
Sensei Biotherapeutics
mbiega@senseibio.com
Media Contact:
Chris Railey
Ten Bridge Communications
chris@tenbridgecommunications.com
FAQ
When will Sensei Biotherapeutics present at the Jefferies Global Healthcare Conference?
What is the focus of Sensei Biotherapeutics?
What is SNS-101 from Sensei Biotherapeutics?
Where can I watch the Sensei Biotherapeutics presentation?